Edition:
United Kingdom

Obseva SA (OBSV.OQ)

OBSV.OQ on NASDAQ Stock Exchange Global Select Market

16.62USD
20 Jul 2018
Change (% chg)

$0.06 (+0.36%)
Prev Close
$16.56
Open
$16.56
Day's High
$17.00
Day's Low
$16.56
Volume
21,516
Avg. Vol
21,924
52-wk High
$20.31
52-wk Low
$6.20

Chart for

About

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109, an oral gonadotropin-releasing hormone (GnRH) receptor... (more)

Overall

Beta: --
Market Cap(Mil.): $257.50
Shares Outstanding(Mil.): 29.63
Dividend: --
Yield (%): --

Financials

  OBSV.OQ Industry Sector
P/E (TTM): -- 85.33 32.76
EPS (TTM): -1.86 -- --
ROI: -66.09 2.22 14.61
ROE: -68.51 3.86 16.34

ObsEva plans Swiss listing; trading debut on July 13

ZURICH ObsEva , a Switzerland-based drug development company, said on Friday it plans a secondary listing on the SIX Swiss Exchange in Zurich and trading debut on July 13, as the firm seeks to gain more visibility among European investors.

06 Jul 2018

UPDATE 1-ObsEva plans Swiss listing; trading debut on July 13

ZURICH, July 6 ObsEva, a Switzerland-based drug development company, said on Friday it plans a secondary listing on the SIX Swiss Exchange in Zurich and trading debut on July 13, as the firm seeks to gain more visibility among European investors.

06 Jul 2018

ObsEva plans Swiss listing; trading debut on July 13

ZURICH, July 6 ObsEva, a Switzerland-based drug development company, said on Friday it is keen on a secondary listing on the SIX Swiss Exchange in Zurich, with a trading debut on July 13, as the firm seeks to gain more notice from European investors.

06 Jul 2018

BRIEF-ObsEva Reports Q4 Loss Per Share $0.48

* OBSEVA REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

09 Mar 2018

BRIEF-Obseva Q4 Loss Per Share $0.48

* OBSEVA REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

09 Mar 2018

BRIEF-Obseva Reports Positive Topline Results From Implant2 Phase 3 Clinical Trial Of Nolasiban In IVF

* OBSEVA SA REPORTS POSITIVE TOPLINE RESULTS FROM IMPLANT2 PHASE 3 CLINICAL TRIAL OF NOLASIBAN IN IVF

26 Feb 2018

BRIEF-Obseva SA Files For Mixed Shelf Of Upto $200 Mln

* OBSEVA SA FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING Source text : http://bit.ly/2rZEClR Further company coverage:

01 Feb 2018

Earnings vs. Estimates